- Home
- CHT vs ALNY Comparison
CHT vs ALNY Comparison
Compare CHT & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHT
- ALNY
- Stock Information
- Founded
- CHT 1996
- ALNY 2002
- Country
- CHT Taiwan
- ALNY United States
- Employees
- CHT N/A
- ALNY N/A
- Industry
- CHT Telecommunications Equipment
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- CHT Telecommunications
- ALNY Health Care
- Exchange
- CHT Nasdaq
- ALNY Nasdaq
- Market Cap
- CHT 29.3B
- ALNY 33.2B
- IPO Year
- CHT 2003
- ALNY 2004
- Fundamental
- Price
- CHT $38.94
- ALNY $278.76
- Analyst Decision
- CHT
- ALNY Buy
- Analyst Count
- CHT 0
- ALNY 24
- Target Price
- CHT N/A
- ALNY $299.09
- AVG Volume (30 Days)
- CHT 93.1K
- ALNY 581.0K
- Earning Date
- CHT 01-23-2025
- ALNY 02-13-2025
- Dividend Yield
- CHT 3.77%
- ALNY N/A
- EPS Growth
- CHT 0.86
- ALNY N/A
- EPS
- CHT 0.15
- ALNY N/A
- Revenue
- CHT $7,017,266,547.00
- ALNY $2,094,795,000.00
- Revenue This Year
- CHT $3.83
- ALNY $24.87
- Revenue Next Year
- CHT $2.03
- ALNY $18.53
- P/E Ratio
- CHT $25.99
- ALNY N/A
- Revenue Growth
- CHT 3.06
- ALNY 21.54
- 52 Week Low
- CHT $35.92
- ALNY $141.98
- 52 Week High
- CHT $40.62
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- CHT 67.93
- ALNY 68.02
- Support Level
- CHT $37.44
- ALNY $245.69
- Resistance Level
- CHT $38.18
- ALNY $256.93
- Average True Range (ATR)
- CHT 0.47
- ALNY 10.40
- MACD
- CHT 0.19
- ALNY 4.74
- Stochastic Oscillator
- CHT 91.73
- ALNY 98.13
About CHT Chunghwa Telecom Co. Ltd.
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company segment consists of Consumer Business, Enterprise Business, International Business, and Others. The company generates the majority of its revenue from the Consumer Business segment. The consumer Business segment generates revenue from Mobile services, Fixed-line services, Sales, and others.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.